Pfenex Inc. Shareholders Who Have Suffered Losses Greater Than $50K Encouraged To Contact Kehoe Law Firm, P.C.

Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of shareholders Pfenex Inc. (“Pfenex” or the “Company”) (NYSE: PFNX) to determine whether Pfenex and certain of the Company’s officers and/or directors committed securities fraud. 

Pfenex, in an April 14, 2020 press release, stated that the FDA “ . . . informed Alvogen Malta Operations Ltd., the Company’s commercialization partner for PF708, via a General Advice letter that additional comparative use human factors (CUHF) data, specifically from Forteo® (teriparatide injection) experienced users, would be required before PF708 Therapeutic Equivalence (TE) could be determined.”

On this news, Pfenex stock dropped $2.49 per share, or 27.85%, to close at $6.45 per share on April 15, 2020.

Pfenex investors who purchased, or otherwise acquired, Pfenex common stock and suffered losses greater than $50K are encouraged to contact Kehoe Law Firm, P.C., John Kehoe, Esq., (215) 792-6676, Ext. 801, [email protected], [email protected], to discuss the securities investigation or potential legal claims.

Kehoe Law Firm, P.C.